Maximizing the power of targeted therapies
Since its FDA approval for CLL treatment in 2014, the targeted-therapy ibrutinib has made chemotherapy regimens a treatment strategy of the past for some patients. But this therapy does not cure CLL and can cause undesired side effects - so we’re not stopping yet. We’re improving our targeted-therapy approach by optimizing the dosage of ibrutinib and combining it with additional drugs. We’re also investigating drugs that treat CLL through mechanisms similar and different to ibrutinib, but with increased efficiency. These new drugs can then be used as single agents, or in combination with other drugs.